MedTrace Logo

Cumulative Irritation Test

NCT00781664 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-04-16

No results posted yet for this study

Summary

The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.

Conditions

  • Tinea Pedis

Interventions

OTHER

AN2718

AN2718 Cream SF Vehicle, Daily for up to 21 days

DRUG

AN2718

AN2718 Cream SF, 0.3%, Daily for up to 21 days

DRUG

AN2718

AN2718 Cream SF, 1%, Daily for up to 21 days

OTHER

AN2718

AN2718 Gel Vehicle, Daily for up to 21 days

DRUG

AN2718

AN2718 Gel, 1.5%, Daily for up to 21 days

DRUG

AN2718

AN2718 Gel, 2.5%, Daily for up to 21 days

DRUG

AN2718

AN2718 Gel, 5%, Daily for up to 21 days

DRUG

AN2718

AN2718 Gel, 7.5%, Daily for up to 21 days

OTHER

Sodium Lauryl Sulfate

Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00781664 on ClinicalTrials.gov